News

Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for CARDAMYST® (etripamil) nasal spray for the conversion of acute symptomatic episodes

Everest Medicines has received approval from China’s National Medical Products Administration (NMPA) for CARDAMYST® (etripamil) nasal spray for the conversion of acute symptomatic episodes

Juniper Biosciences has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for JBS-003 (18F-fluoromisonidazole or FMISO), a hypoxia tracer being developed to guide reduced radiation therapy in patients with HPV-positive oropharyngeal carcinoma (OPC).

Cipla and Sino Biopharmaceutical (SBP Group) have entered into an exclusive licensing and supply agreement for Rolditamig Deuderuxtecan, also known as TQB2102, a HER2-targeted bispecific antibody-drug conjugate (ADC) being developed for the treatment of cancer.

The US Food and Drug Administration (FDA) has approved Revolution Medicines’ RASONQUE™ (daraxonrasib) tablets for adults with metastatic pancreatic adenocarcinoma (PDAC) who have received at least one previous systemic treatment or are not candidates for multi-agent systemic therapy.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has received accelerated approval from the U.S. Food and Drug Administration (FDA) for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, for adults and children aged eight years and older with glycogen storage disease type Ia (GSDIa).

Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited, a Hyderabad-based contract development and manufacturing organisation (CDMO) specialising in vaccines and biologics.

Tagomics Ltd., a precision medicine company, has launched LiquiPath™, a cross-species, multi-organ liquid pathology platform designed for non-invasive drug safety monitoring. The platform is intended for use

Photys Therapeutics, Inc. (“Photys”), a proximity-based therapeutics company, and Polymed Biopharmaceuticals, Inc. (“Polymed”), a global biotech company focused on creating best-in-class PROTACs

Aurisco Pharmaceutical has announced that its manufacturing site in Yangzhou, China, has successfully completed a US Food and Drug Administration (FDA) inspection, making it the first generic oligonucleotide active pharmaceutical ingredient (API) manufacturer to pass a US FDA inspection, according to the company.